Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and ...
Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...
Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...
Pharmaceutical Technology on MSN14h
FDA approves Gomekli as first neurofibromatosis drug for adultsThe US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two ...
Edris Badreddin, Chief Operating Officer of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), sold 30,000 shares of the company's ...
Recent health news highlights include Gilead's upbeat 2025 forecast, Edwards Lifesciences surpassing profit estimates, New ...
Julie Hambleton, a director at SpringWorks Therapeutics Inc . (NASDAQ:SWTX), recently sold shares valued at approximately $730,206, according to a recent SEC filing. The transaction involved the sale ...
TD Cowen raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $66 from $63 and keeps a Buy rating on the shares. The firm says ...
The FDA's green light for GOMEKLI is a significant achievement for SpringWorks, especially as it comes with a rare pediatric disease priority review voucher, which could be valued at around $100 ...
The US Food and Drug Administration approved Gomekli (mirdametinib), from SpringWorks Therapeutics, a kinase inhibitor, for adult and pediatric patients two years of age and older with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback